Cargando…

Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy

INTRODUCTION: Hematologic toxicity (HT) is a joint adverse event after CAR-T cells infusion. Some patients experience prolonged hematologic toxicity (PHT), which is challenging to treat. METHODS: We collected clinical data from patients with relapsed refractory B-ALL treated with CD19 CAR-T cells. P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jiaxi, Zhang, Meng, Lyu, Hairong, Guo, Ruiting, Xiao, Xia, Bai, Xue, Pu, Yedi, Meng, Juanxia, Li, Qing, Yuan, Ting, Lu, Wenyi, Zhao, Mingfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043253/ https://www.ncbi.nlm.nih.gov/pubmed/36999027 http://dx.doi.org/10.3389/fimmu.2023.1139559

Ejemplares similares

Metagenomic Next-Generation Sequencing for Diagnostically Challenging Mucormycosis in Patients with Hematological Malignancies
por: Zhang, Meng, et al.
Publicado: (2022)

The Value of Metagenomic Next-Generation Sequencing in Hematological Malignancy Patients with Febrile Neutropenia After Empiric Antibiotic Treatment Failure
por: Zhang, Meng, et al.
Publicado: (2022)

Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies
por: Cao, Xinping, et al.
Publicado: (2023)

A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients
por: Lu, Wenyi, et al.
Publicado: (2022)

CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
por: Jin, Xin, et al.
Publicado: (2023)

First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
por: Jin, Xin, et al.
Publicado: (2022)

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
por: Lu, Wenyi, et al.
Publicado: (2021)

Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL
por: He, Xiaoyuan, et al.
Publicado: (2019)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial
por: Rak, Mariola B., et al.
Publicado: (2023)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances
por: Liu, Jile, et al.
Publicado: (2023)

Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma
por: Li, Hujun, et al.
Publicado: (2022)

Effects of Oral Prednisone Administration on Serum Cystatin C in Dogs
por: Muñoz, J., et al.
Publicado: (2017)

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
por: Xie, Danni, et al.
Publicado: (2022)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

The journey of CAR-T therapy in hematological malignancies
por: Lu, Junru, et al.
Publicado: (2022)

Methylprednisolone/prednisone: Various toxicities: case report
Publicado: (2022)

Tozinameran/prednisone: Various toxicities: case report
Publicado: (2022)

Cyclophosphamide/doxorubicin/prednisone: Prolonged COVID-19 viral shedding, neutropenia and thrombocytopenia: case report
Publicado: (2021)

Editorial: CAR T-Cell Therapies in Hematologic Tumors
por: Coscia, Marta, et al.
Publicado: (2020)

T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies
por: Tang, Lu, et al.
Publicado: (2021)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
por: Jin, Xin, et al.
Publicado: (2019)

Tear Fluid Pharmacokinetics Following Oral Prednisone Administration in Dogs With and Without Conjunctivitis
por: Sebbag, Lionel, et al.
Publicado: (2019)

Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
por: Wang, Jia, et al.
Publicado: (2020)

Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice
por: Jin, Xin, et al.
Publicado: (2018)

Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
por: Liu, Meijing, et al.
Publicado: (2021)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report
por: Chantelau, Ernst A, et al.
Publicado: (2011)

CAR T Cell Therapy in Hematological Malignancies: Implications of the Tumor Microenvironment and Biomarkers on Efficacy and Toxicity
por: Tan, Jing Yuan, et al.
Publicado: (2022)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice
por: Chai, Xiao, et al.
Publicado: (2015)

Corrigendum: ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice
por: Chai, Xiao, et al.
Publicado: (2017)

Hematologic Rescue of CAR T-cell–mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient
por: Gödel, Philipp, et al.
Publicado: (2021)

Urinary excretion profile of prednisolone and prednisone after rectal administration: Significance in antidoping analysis
por: Iannella, Loredana, et al.
Publicado: (2022)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

Gene Modified CAR-T Cellular Therapy for Hematologic Malignancies
por: Lin, Wen-Ying, et al.
Publicado: (2020)

Current Progress in CAR-T Cell Therapy for Hematological Malignancies
por: Han, Donglei, et al.
Publicado: (2021)

The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
por: Guo, Zilong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e66ppsluhk3l63pibiprj0o7te